Key Highlights
- Net revenues rose 13.0% to USD 78.0 million for the quarter ended September 30, 2026, from USD 69.0 million, on higher Jeuveau and Evolysse sales.
- Net loss narrowed to USD 12.5 million, or USD 0.19 per share, from USD 15.7 million, or USD 0.24, while loss from operations fell to USD 8.4 million from USD 11.5 million.
- Gross profit margin slipped to 65.0% from 66.5%, and the nine-month net loss narrowed to USD 31.2 million from USD 51.8 million.
- Cash and cash equivalents were USD 41.7 million on September 30, 2026, against a stockholders' Deficit of USD 37.8 million and an accumulated deficit of USD 692.3 million.
Revenue Growth Cuts the Loss but Margin Slips
Evolus (NASDAQ:EOLS) filed its Quarterly Report on November 4, 2026. The company sells Jeuveau, a neuromodulator, and Evolysse hyaluronic acid gels to licensed aesthetic practitioners in a cash-pay market. Product Revenue was USD 77.2 million, and USD 0.7 million of service revenue came from Jeuveau sold through a distribution partner in Canada. Cost of Goods Sold rose 17.9% to USD 27.3 million on higher volumes, outpacing sales and trimming gross margin. Selling, general and administrative expense stayed at USD 52.9 million, so growth flowed to the bottom line. A USD 1.6 million Revaluation charge on a contingent Royalty obligation partly offset that benefit. Interest expense, net rose to USD 4.0 million on lower interest income and higher debt, including Pharmakon term loans and a revolving Credit facility.
Tariff-Driven Inventory Build and Deferred Payments
Because of uncertainty over possible tariffs on Korean-made pharmaceutical products, the company accelerated imports of Jeuveau under a deferred payment arrangement. Since December 31, 2025, inventories rose USD 55.8 million and Accounts Payable rose USD 62.8 million, with payments generally deferred until the related inventory is sold. Evolysse, imported from the European Union, faces a 10% Section 301 Tariff after a prior temporary tariff expired on July 24, 2026. After Commerce guidance in September 2026, the company does not currently expect Jeuveau to face Section 232 tariffs, though policy can change. Nine-month operating cash use was USD 15.5 million against USD 55.1 million.
Profhilo, Symatese Rights and a Hair Regrowth Option
On July 7, 2026 the company licensed Profhilo for U.S. aesthetics from IBSA with no upfront or milestone payment, targeting commercialization in 2030 if approved. In August 2026 it expanded Evolysse rights to Europe, Canada, Australia and New Zealand, with upfront payments of 1.4 million euros and up to 2.9 million euros more on approvals, which also produced USD 1.1 million of in-process R&D expense. An October 12 option on a hair regrowth injectable carries USD 1.5 million of option consideration and a USD 7.5 million upfront payment if exercised. Nine-month gross profit was USD 156.8 million, and revenue was USD 235.2 million against USD 206.9 million, and the net loss per share was USD 0.48 against USD 0.80.
Where Things Stand
The loss narrowed because revenue grew 13.0% while overhead stayed flat, not because of a higher margin. Evolus (NASDAQ:EOLS) still reported a USD 12.5 million net loss, and its Balance Sheet shows a stockholders' deficit and USD 41.7 million of cash after the inventory build. Next markers are US approvals for Evolysse Sculpt and Evolysse Lips in 2026 and 2027, tariff treatment of Jeuveau and the timing of deferred supplier payments.






Please wait processing your request...